• Hospital admissions from alcohol-related acute pancreatitis during the COVID-19 pandemic: A single-centre study 

  Mak, W. K.; Di Mauro, D.; Pearce, E.; Karran, L.; Myintmo, A.; Duckworth, J.; Orabi, A.; Lane, R.; Holloway, S.; Manzelli, A.; Mossadegh, S. (IS Publishing, 2022-09-06)

  BACKGROUND: The United Kingdom government introduced lockdown restrictions for the first time on 23 March 2020 due to coronavirus disease 2019 (COVID-19) pandemic. These were partially lifted on 15 June and further eased ...

• Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK 

  Sinclair, R. C. F.; Nadaraja, S.; Kennedy, N. A.; Wakatsuki, M.; Bhandari, S. (Nature, 2022-11-07)

  Ferric derisomaltose (FDI; Monofer) is used in clinical practice to treat iron deficiency, but the safety and efficacy of FDI has not been robustly evaluated in a large real-world study. This retrospective, multicentre, ...

• Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients Following 3 Doses of COVID-19 Vaccine 

  Liu, Z.; Alexander, J. L.; Lin, K. W.; Ahmad, T.; Pollock, K. M.; Powell, N. (Elsevier, 2022-10-19)

• Surgical Methods of Fistula Closure in fistulating perianal Crohn's Disease 

  Khalil, I.; Bethune, R. (Wiley, 2022-11-25)

• Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic 

  Lin, S.; Lau, L. H.; Chanchlani, N.; Kennedy, N. A.; Ng, S. C. (BMJ, 2022-07-01)

  The COVID-19 pandemic has raised considerable concerns that patients with inflammatory bowel disease (IBD), particularly those treated with immunosuppressive therapies, may have an increased risk of SARS-CoV-2 acquisition, ...

• Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic 

  Kennedy, N. A.; Janjua, M.; Chanchlani, N.; Lin, S.; Bewshea, C.; Nice, R.; McDonald, T. J.; Auckland, C.; Harries, L. W.; Davies, M.; Michell, S.; Kok, K. B.; Lamb, C. A.; Smith, P. J.; Hart, A. L.; Pollok, R. C.; Lees, C. W.; Boyton, R. J.; Altmann, D. M.; Sebastian, S.; Powell, N.; Goodhand, J. R.; Ahmad, T. (BMJ, 2022-07-28)

  OBJECTIVE: Antitumour necrosis factor (TNF) drugs impair serological responses following SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-based vaccine substantially boosted anti-SARS-CoV-2 ...

• Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease? 

  Lin, S.; Chanchlani, N.; Carbery, I.; Janjua, M.; Nice, R.; McDonald, T. J.; Bewshea, C.; Kennedy, N. A.; Ahmad, T.; Selinger, C. P.; Goodhand, J. R. (Wiley, 2022-09-01)

  BACKGROUND: During illness, adaptations of the hypothalamic-pituitary-thyroid axis reduce energy expenditure, protein catabolism and modulate immune responses to promote survival. Lower serum free triiodothyronine-to-thyroxine ...

• Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform 

  MacKenna, B.; Kennedy, N. A.; Mehrkar, A.; Rowan, A.; Galloway, J.; Matthewman, J.; Mansfield, K. E.; Bechman, K.; Yates, M.; Brown, J.; Schultze, A.; Norton, S.; Walker, A. J.; Morton, C. E.; Harrison, D.; Bhaskaran, K.; Rentsch, C. T.; Williamson, E.; Croker, R.; Bacon, S.; Hickman, G.; Ward, T.; Davy, S.; Green, A.; Fisher, L.; Hulme, W.; Bates, C.; Curtis, H. J.; Tazare, J.; Eggo, R. M.; Evans, D.; Inglesby, P.; Cockburn, J.; McDonald, H. I.; Tomlinson, L. A.; Mathur, R.; Wong, A. Y. S.; Forbes, H.; Parry, J.; Hester, F.; Harper, S.; Douglas, I. J.; Smeeth, L.; Lees, C. W.; Evans, S. J. W.; Goldacre, B.; Smith, C. H.; Langan, S. M. (Elsevier, 2022-06-15)

  BACKGROUND: The risk of severe COVID-19 outcomes in people with immune-mediated inflammatory diseases and on immune-modifying drugs might not be fully mediated by comorbidities and might vary by factors such as ethnicity. ...

• COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study 

  Alexander, J. L.; Liu, Z.; Muñoz Sandoval, D.; Reynolds, C.; Ibraheim, H.; Anandabaskaran, S.; Saifuddin, A.; Castro Seoane, R.; Anand, N.; Nice, R.; Bewshea, C.; D'Mello, A.; Constable, L.; Jones, G. R.; Balarajah, S.; Fiorentino, F.; Sebastian, S.; Irving, P. M.; Hicks, L. C.; Williams, H. R. T.; Kent, A. J.; Linger, R.; Parkes, M.; Kok, K.; Patel, K. V.; Teare, J. P.; Altmann, D. M.; Goodhand, J. R.; Hart, A. L.; Lees, C. W.; Boyton, R. J.; Kennedy, N. A.; Ahmad, T.; Powell, N. (Elsevier, 2022-09-08)

  BACKGROUND: COVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We sought to assess whether immunosuppressive ...

• A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report 

  Rowan, A.; Bates, C.; Hulme, W.; Evans, D.; Davy, S.; N, A. Kennedy; Galloway, J.; K, E. Mansfield; Bechman, K.; Matthewman, J.; Yates, M.; Brown, J.; Schultze, A.; Norton, S.; A, J. Walker; C, E. Morton; Bhaskaran, K.; C, T. Rentsch; Williamson, E.; Croker, R.; Bacon, S.; Hickman, G.; Ward, T.; Green, A.; Fisher, L.; H, J. Curtis; Tazare, J.; R, M. Eggo; Inglesby, P.; Cockburn, J.; H, I. McDonald; Mathur, R.; Ys Wong, A.; Forbes, H.; Parry, J.; Hester, F.; Harper, S.; I, J. Douglas; Smeeth, L.; L, A. Tomlinson; C, W. Lees; Evans, S.; Smith, C.; S, M. Langan; Mehkar, A.; MacKenna, B.; Goldacre, B. (Wellcome, 2022-06-01)

  Background: At the outset of the COVID-19 pandemic, there was no routine comprehensive hospital medicines data from the UK available to researchers. These records can be important for many analyses including the effect of ...

• The first international Delphi consensus statement on Laparoscopic Gastrointestinal surgery 

  Omar, I.; Miller, K.; Madhok, B.; Amr, B.; Singhal, R.; Graham, Y.; Pouwels, S.; Abu Hilal, M.; Aggarwal, S.; Ahmed, I.; Aminian, A.; Ammori, B. J.; Arulampalam, T.; Awan, A.; Balibrea, J. M.; Bhangu, A.; Brady, R. R.; Brown, W.; Chand, M.; Darzi, A.; Gill, T. S.; Goel, R.; Gopinath, B. R.; Henegouwen, M. V. B.; Himpens, J. M.; Kerrigan, D. D.; Luyer, M.; Macutkiewicz, C.; Mayol, J.; Purkayastha, S.; Rosenthal, R. J.; Shikora, S. A.; Small, P. K.; Smart, N. J.; Taylor, M. A.; Udwadia, T. E.; Underwood, T.; Viswanath, Y. K.; Welch, N. T.; Wexner, S. D.; Wilson, M. S. J.; Winter, D. C.; Mahawar, K. K. (Elsevier, 2022-08-01)

  BACKGROUND: Laparoscopic surgery has almost replaced open surgery in many areas of Gastro-Intestinal (GI) surgery. There is currently no published expert consensus statement on the principles of laparoscopic GI surgery. ...

• Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients 

  Ricciuto, A.; Lamb, C. A.; Benchimol, E. I.; Walker, G. J.; Kennedy, N. A.; Kuenzig, M. E.; Kaplan, G. G.; Kappelman, M. D.; Ungaro, R. C.; Colombel, J. F.; Brenner, E. J.; Agrawal, M.; Reinisch, W.; Griffiths, A. M.; Sebastian, S. (Oxford University Press, 2022-05-10)

  BACKGROUND AND AIMS: Age is a major prognostic factor for COVID-19 outcomes. The effect of inflammatory bowel disease [IBD] activity on COVID-19 is unclear. We examined the relationship between IBD activity and COVID-19 ...

• Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity 

  Lees, C. W.; Ahmad, T.; Lamb, C. A.; Powell, N.; Din, S.; Cooney, R.; Kennedy, N. A.; Ainley, R.; Wakeman, R.; Selinger, C. P. (BMJ, 2022-05-05)

• Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study 

  Chanchlani, N.; Lin, S.; Auth, M. K.; Lee, C. L.; Robbins, H.; Looi, S.; Murugesan, S. V.; Riley, T.; Preston, C.; Stephenson, S.; Cardozo, W.; Sonwalkar, S. A.; Allah-Ditta, M.; Mansfield, L.; Durai, D.; Baker, M.; London, I.; London, E.; Gupta, S.; Di Mambro, A.; Murphy, A.; Gaynor, E.; Jones, K. D. J.; Claridge, A.; Sebastian, S.; Ramachandran, S.; Selinger, C. P.; Borg-Bartolo, S. P.; Knight, P.; Sprakes, M. B.; Burton, J.; Kane, P.; Lupton, S.; Fletcher, A.; Gaya, D. R.; Colbert, R.; Seenan, J. P.; MacDonald, J.; Lynch, L.; McLachlan, I.; Shields, S.; Hansen, R.; Gervais, L.; Jere, M.; Akhtar, M.; Black, K.; Henderson, P.; Russell, R. K.; Lees, C. W.; Derikx, Laap; Lockett, M.; Betteridge, F.; De Silva, A.; Hussenbux, A.; Beckly, J.; Bendall, O.; Hart, J. W.; Thomas, A.; Hamilton, B.; Gordon, C.; Chee, D.; McDonald, T. J.; Nice, R.; Parkinson, M.; Gardner-Thorpe, H.; Butterworth, J. R.; Javed, A.; Al-Shakhshir, S.; Yadagiri, R.; Maher, S.; Pollok, R. C. G.; Ng, T.; Appiahene, P.; Donovan, F.; Lok, J.; Chandy, R.; Jagdish, R.; Baig, D.; Mahmood, Z.; Marsh, L.; Moss, A.; Abdulgader, A.; Kitchin, A.; Walker, G. J.; George, B.; Lim, Y. H.; Gulliver, J.; Bloom, S.; Theaker, H.; Carlson, S.; Cummings, J. R. F.; Livingstone, R.; Beale, A.; Carter, J. O.; Bell, A.; Coulter, A.; Snook, J.; Stone, H.; Kennedy, N. A.; Goodhand, J. R.; Ahmad, T. (Wiley, 2022-08-29)

  BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD). AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would ...

• Multisystem inflammatory syndrome in children 

  Chanchlani, N.; Chesshyre, E.; Hart, J. W. (Canadian Medical Association, 2022-07-11)

• Outcomes of patients with non-lower gastrointestinal cancer diagnosed via the lower gastrointestinal two-week-wait service 

  Hubbard, T.; Burton, H.; Pringle, H.; Bethune, R.; McDermott, F. D. (Royal College of Surgeons, 2022-05-26)

  INTRODUCTION: Patients referred via lower gastrointestinal two-week-wait (LGI-2WW) services deemed at 'low risk' of LGI cancer may have delayed or no investigation. However, 20% of patients diagnosed with cancer via the ...

• Clinician preferences in the treatment of acutely symptomatic hernia: the 'MASH' survey 

  O'Connor, O. M.; Burns, F. A.; Proctor, V. K.; Green, S. K.; Sayers, A. E.; Smart, N. J.; Lee, M. J. (Royal College of Surgeons, 2022-02-23)

  INTRODUCTION: There is limited high-quality evidence to guide the management of acute hernia presentation. The aim of this study was to survey surgeons to assess current trends in assessment, treatment strategy and operative ...

• Elective splenectomy in patients with non-Hodgkin lymphoma: Does the size of the spleen affect surgical outcomes? 

  Mauro, D. D.; Gelsomino, M.; Fasano, A.; Wajed, S.; Manzelli, A. (Korean Association of Hepato-Biliary-Pancreatic Surgery, 2022-02-16)

  BACKGROUNDS/AIMS: Splenectomy in patients with non-Hodgkin lymphoma (NHL) is performed to relieve abdominal symptoms, treat hypersplenism or confirm diagnosis. Excision of a very large spleen is technically challenging and ...

• Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study 

  Sebastian, S.; Patel, K. V.; Segal, J. P.; Subramanian, S.; Conley, T. E.; Gonzalez, H. A.; Kent, A. J.; Saifuddin, A.; Hicks, L.; Mehta, S.; Bhala, N.; Brookes, M. J.; Lamb, C. A.; Kennedy, N. A.; Walker, G. J. (BMJ Publishing Group, 2022-01-01)

  INTRODUCTION: Acute severe ulcerative colitis (ASUC) traditionally requires inpatient hospital management for intravenous therapies and/or colectomy. Ambulatory ASUC care has not yet been evaluated in large cohorts. AIMS: ...

• Editor's Choice - February 2022 

  Smart, N. (Wiley, 2022-02-01)

View more